2,237 results match your criteria American Journal of Cancer Research[Journal]


ATR inhibition sensitizes liposarcoma to doxorubicin by increasing DNA damage.

Am J Cancer Res 2022 15;12(4):1577-1592. Epub 2022 Apr 15.

Department of Orthopedic Surgery, Sarcoma Biology Laboratory, Sylvester Comprehensive Cancer Center, and The University of Miami Miller School of Medicine, Papanicolaou Cancer Research Building 1550 NW. 10th Avenue, Miami, Florida 33136, USA.

Liposarcomas account for approximately 20% of all adult sarcomas and have limited therapeutic options outside of surgery. Inhibition of ataxia-telangiectasia and Rad3 related protein kinase (ATR) has emerged as a promising chemotherapeutic strategy in various cancers. However, its activation, expression, and function in liposarcoma remain unkown. Read More

View Article and Full-Text PDF

Identification of novel biomarkers differentially expressed between African-American and Caucasian-American prostate cancer patients.

Am J Cancer Res 2022 15;12(4):1660-1670. Epub 2022 Apr 15.

Department of Pathology, New York University School of Medicine New York, USA.

Prostate cancer (PCa) incidence and mortality rate vary among racial and ethnic groups with the highest occurrence in African American (AA) men who have mortality rates twice that of Caucasians (CA). In this study, we focused on differential expression of proteins in AA prostate cancer compared to CA using Protein Pathway Array Analysis (PPAA), in order to identify protein biomarkers associated with PCa racial disparity. Fresh frozen prostate samples (n=90) obtained from radical prostatectomy specimens with PCa, including 25 AA tumor, 21 AA benign, 23 CA tumor, 21 CA benign samples were analyzed. Read More

View Article and Full-Text PDF

Signature of the vascular tumor microenvironment as a marker of the therapeutic response to doxorubicin in a preclinical model of osteosarcoma.

Am J Cancer Res 2022 15;12(4):1843-1854. Epub 2022 Apr 15.

Nantes University INSERM UMR 1238, Nantes, France.

Predicting a response of osteosarcoma patients to chemotherapy, such as doxorubicin or high-dose methotrexate cocktail, remains a challenge in the clinic. Moreover, the prognostic value of currently used necrosis analysis is debatable. New markers of the therapeutic response or the prognostic response are urgently needed. Read More

View Article and Full-Text PDF

Construction and validation of a biochemical signature to predict the prognosis and the benefit of induction chemotherapy in patients with nasopharyngeal carcinoma.

Am J Cancer Res 2022 15;12(4):1635-1647. Epub 2022 Apr 15.

Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy Guangzhou, Guangdong 510060, P. R. China.

This study aimed to develop and validate a biochemical signature for predicting the prognosis of patients with nasopharyngeal carcinoma (NPC) and explore roles of the constructed signature for screening optimal candidates for induction chemotherapy (IC). The biochemical signature was constructed based on a retrospective cohort of 3742 patients from January 2008 to December 2010; 2078 patients from prospective studies from January 2011 to December 2012 and 2153 patients from January 2013 to December 2016 served as validation cohort A and validation cohort B. Overall survival (OS) was the primary endpoint. Read More

View Article and Full-Text PDF

DNA repair proteins as the targets for paroxetine to induce cytotoxicity in gastric cancer cell AGS.

Am J Cancer Res 2022 15;12(4):1465-1483. Epub 2022 Apr 15.

Institute of Biomedical Sciences, National Chung Hsing University Taichung 402, Taiwan.

To evaluate the potential anticancer effects of 1175 FDA-approved drugs, cell viability screening was performed using 25 human cancer cell lines covering 14 human cancer types. Here, we focus on the action of paroxetine, which demonstrated greater toxicity toward human gastric adenocarcinoma cell-line AGS cells compared with the other FDA-approved drugs, exhibiting an IC50 value lower than 10 μM. Evaluation of the underlying novel mechanisms revealed that paroxetine can enhance DNA damage in gastric cancer cells and involves downregulation of Rad51, HR23B and ERCC1 expression and function, as well as nucleotide shortage. Read More

View Article and Full-Text PDF

Oncogenic ACSM1 in prostate cancer is through metabolic and extracellular matrix-receptor interaction signaling pathways.

Am J Cancer Res 2022 15;12(4):1824-1842. Epub 2022 Apr 15.

Department of Pathology, Mudanjiang Medical University Mudanjiang 157011, China.

Acyl-coenzyme A synthetase medium chain family member 1 (ACSM1) is a medium chain Acyl-CoA Synthetase family member and plays an important role in fatty acid metabolism. The oncogenic roles of ACSM1 are largely unknown. Using comprehensive approaches, we analyzed gene expression profiles and genomic datasets and identified that the expression of ACSM1 was specifically increased in prostate cancer in comparison to the adjacent non-tumor tissues. Read More

View Article and Full-Text PDF

The role of Fbxo5 in the development of human malignant tumors.

Am J Cancer Res 2022 15;12(4):1456-1464. Epub 2022 Apr 15.

Department of Biochemistry and Molecular Biology, School of Laboratory Medicine, Bengbu Medical College Bengbu 233030, Anhui, China.

Fbxo5 (F-Box only protein 5), as a substrate recognition subunit of SCF (SKP1-Cullin1-Fbox) protein, plays a crucial role in various cellular processes through ubiquitination and degradation of multiple proteins. In recent years, many studies have pointed out that Fbxo5 is critically involved in carcinogenesis. Moreover, targeting Fbxo5 could have a therapeutic potential for cancer therapy. Read More

View Article and Full-Text PDF

The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan.

Am J Cancer Res 2022 15;12(4):1884-1898. Epub 2022 Apr 15.

Division of General Surgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University Tainan, Taiwan.

Nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (NalFL) comprises the current standard for gemcitabine-failed metastatic pancreatic ductal adenocarcinoma (PDAC). As liposomes generally accumulate in the spleen, we evaluated the impact of spleen volume on prognosis. We enrolled patients with metastatic PDAC who failed gemcitabine-based therapy and were initiated on NalFL between August 2018 and November 2020. Read More

View Article and Full-Text PDF

Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma.

Am J Cancer Res 2022 15;12(4):1606-1620. Epub 2022 Apr 15.

Department of Gastroenterology and Hepatology, Linkuo Chang Gung Memorial Hospital, Chang Gung University Taiwan.

Anti-Programmed cell Death protein 1 (Anti-PD1) or Programmed Death-Ligand 1 (PDL1) immune checkpoint inhibitors provide treatment options for advanced HCC patients with low response rates. Combination therapy is becoming a major issue to improve the unmet need. Proton beam radiotherapy (PBT) could effectively control the local tumor with a low-risk injury to peripheral liver parenchyma. Read More

View Article and Full-Text PDF

Differential effects of glucose and N-acetylglucosamine on genome instability.

Am J Cancer Res 2022 15;12(4):1556-1576. Epub 2022 Apr 15.

Genomics Research Center, Academia Sinica Taipei 11529, Taiwan.

Aberrant sugar metabolism is linked to an increased risk of pancreatic cancer. Previously, we found that high glucose induces genome instability and oncogenic mutation preferentially in pancreatic cells through dysregulation of O-GlcNAcylation. Increasing O-GlcNAcylation by extrinsically supplying N-acetyl-D-glucosamine (GlcNAc) causes genome instability in all kinds of cell types regardless of pancreatic origin. Read More

View Article and Full-Text PDF

Identification of immune-related biomarkers associated with tumorigenesis and prognosis in skin cutaneous melanoma.

Am J Cancer Res 2022 15;12(4):1727-1739. Epub 2022 Apr 15.

Department of Hand and Foot Surgery, First Hospital Jilin University Changchun, Jilin, China.

Skin cutaneous melanoma (SKCM) is one of the most malignant and aggressive forms of cancer. Investigating the mechanisms of carcinogenesis further could lead to the discovery of prognostic biomarkers that could be used to guide cancer treatment. In this study, we conducted integrative bioinformatics analyses of TCGA database, STRING, cBioPortal, TRRUST, The Human Protein Atlas, and DGIdb to determine which hub genes contributed to tumor progression and the cancer-associated immunology of SKCM. Read More

View Article and Full-Text PDF

β-elemene suppresses tumor metabolism and stem cell-like properties of non-small cell lung cancer cells by regulating PI3K/AKT/mTOR signaling.

Am J Cancer Res 2022 15;12(4):1535-1555. Epub 2022 Apr 15.

Department of Encephalopathy, Affiliated Hospital to Changchun University of Chinese Medicine Jilin 130021, China.

Multi-drug resistance remains a critical issue in cancer treatment that hinders the effective use of chemotherapeutic drugs. The active components of traditional Chinese medicine have been applied as adjuvants to accentuate the anticancer properties of conventional drugs such as cisplatin. However, their application requires further validation and optimization. Read More

View Article and Full-Text PDF

Dynamic proteomic change of tumor and immune organs in an immune-competent hepatocellular carcinoma mouse model.

Am J Cancer Res 2022 15;12(4):1621-1634. Epub 2022 Apr 15.

State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics Beijing 102206, China.

Subcutaneous implantation of a human cancer cell line in immune-deficient mice (CDX) is a commonly used tool in preclinical studies for the assessment of potential anti-cancer drugs. As immunotherapy is transforming cancer treatment, tumor models in immunocompetent mice are necessary for us to understand the immune aspects of tumor biology. However, the systemic immune response to the implantation of cancer cells at proteome level is unclear. Read More

View Article and Full-Text PDF

Targeting 2-oxoglutarate dehydrogenase for cancer treatment.

Am J Cancer Res 2022 15;12(4):1436-1455. Epub 2022 Apr 15.

Center for Molecular Medicine, China Medical University Hospital, China Medical University Taichung 404, Taiwan.

Tricarboxylic acid (TCA) cycle, also called Krebs cycle or citric acid cycle, is an amphoteric pathway, contributing to catabolic degradation and anaplerotic reactions to supply precursors for macromolecule biosynthesis. Oxoglutarate dehydrogenase complex (OGDHc, also called α-ketoglutarate dehydrogenase) a highly regulated enzyme in TCA cycle, converts α-ketoglutarate (αKG) to succinyl-Coenzyme A in accompany with NADH generation for ATP generation through oxidative phosphorylation. The step collaborates with glutaminolysis at an intersectional point to govern αKG levels for energy production, nucleotide and amino acid syntheses, and the resources for macromolecule synthesis in cancer cells with rapid proliferation. Read More

View Article and Full-Text PDF

A novel score system for predicting conversion to no evidence of Disease (C-NED) in initially unresectable colorectal cancer liver metastases.

Am J Cancer Res 2022 15;12(4):1648-1659. Epub 2022 Apr 15.

Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Guangzhou 510060, Guangdong, P. R. China.

An estimated 70-80% of cases of colorectal cancer liver metastasis (CRLM) are defined as initially unresectable. "Converting" to no evidence of disease (NED) status may prolong survival. The current study aimed to develop a novel scoring system that predicts the conversion outcome for initially unresectable CRLM. Read More

View Article and Full-Text PDF

Endoscopic features of esophageal high-grade intraepithelial neoplasia dominated by cytological atypia.

Am J Cancer Res 2022 15;12(4):1855-1865. Epub 2022 Apr 15.

Department of Gastroenterology, Xinqiao Hospital, Army Medical University Chongqing 400037, China.

Little is known about esophageal high-grade intraepithelial neoplasia dominated by cytological atypia (HGINc). We aimed to elucidate the endoscopic features of HGINc compared with esophageal high-grade intraepithelial neoplasia dominated by architectural atypia (HGINa). All patients pathologically diagnosed as esophageal high-grade intraepithelial neoplasia after endoscopic submucosal dissection at our center between January 2018 and December 2019 were included in this study. Read More

View Article and Full-Text PDF

The small molecule NLRP3 inhibitor RRx-001 potentiates regorafenib activity and attenuates regorafenib-induced toxicity in mice bearing human colorectal cancer xenografts.

Am J Cancer Res 2022 15;12(4):1912-1918. Epub 2022 Apr 15.

Department of Bioengineering, University of California San Diego La Jolla, CA, USA.

The multi-kinase inhibitor Regorafenib, approved for the treatment of metastatic colorectal cancer, is poorly tolerated with a Grade 3/4 drug related adverse event rate of 54% resulting in frequent dose reductions and discontinuations. RRx-001 is a minimally toxic NLRP3 inhibitor small molecule with macrophage-repolarizing properties in Phase 3 clinical trials. Studies have demonstrated the inhibitory impact of M2 macrophages on the activity of tyrosine kinases, suggesting that the repolarization of macrophages by RRx-001 may enhance the activity of TKIs. Read More

View Article and Full-Text PDF

Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.

Am J Cancer Res 2022 15;12(4):1899-1911. Epub 2022 Apr 15.

Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center Taiwan.

Immune checkpoint inhibitors (ICIs) with atezolizumab plus bevacizumab are promising agents for unresectable hepatocellular carcinoma (HCC). We tried to guide the treatment based on recent developed CRAFITY score combining with on-treatment AFP response. Eighty-nine patients who received atezolizumab plus bevacizumab regardless of as a first-line therapy or not for unresectable HCC were enrolled for analyses. Read More

View Article and Full-Text PDF

Investigation of the effects of overexpression of jumping translocation breakpoint (JTB) protein in MCF7 cells for potential use as a biomarker in breast cancer.

Am J Cancer Res 2022 15;12(4):1784-1823. Epub 2022 Apr 15.

Biochemistry & Proteomics Group, Department of Chemistry and Biomolecular Science, Clarkson University Potsdam, NY 13699-5810, USA.

Jumping translocation breakpoint (JTB) gene acts as a tumor suppressor or an oncogene in different malignancies, including breast cancer (BC), where it was reported as overexpressed. However, the molecular functions, biological processes and underlying mechanisms through which JTB protein causes increased cell growth, proliferation and invasion is still not fully deciphered. Our goal is to identify the functions of JTB protein by cellular proteomics approaches. Read More

View Article and Full-Text PDF

The efficacy and mechanism of thoracic photodynamic therapy mediated by hematoporphyrin injection on disseminated pleural malignancies of Lewis lung carcinoma in mice.

Am J Cancer Res 2022 15;12(4):1502-1510. Epub 2022 Apr 15.

Department of Respiratory and Critical Care Medicine, General Hospital of Tianjin Medical University Tianjin 300052, China.

In order to avoid the problems of long exposure time and high incidence of photosensitivity by intravenous injection of photosensitizer, our study explore the safety, efficacy, and possible mechanisms of photodynamic therapy (PDT) by intrathoracic administration of hematoporphyrin injection in the treatment of disseminated pleural malignancies of Lewis lung carcinoma in mice to provide a theoretical basis for thoracic PDT in the clinic. Hematoporphyrin was administered into the thoracic cavity of tumor-bearing mice, and the concentrations of hematoporphyrin in normal and tumor pleural tissues were detected by high-performance liquid chromatography. The tumor-bearing mice were randomly divided into four groups: model control, pure laser irradiation, PDT low-dose, and PDT high-dose groups. Read More

View Article and Full-Text PDF

E2F1-mediated GINS2 transcriptional activation promotes tumor progression through PI3K/AKT/mTOR pathway in hepatocellular carcinoma.

Am J Cancer Res 2022 15;12(4):1707-1726. Epub 2022 Apr 15.

Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences Nanjing 210029, Jiangsu, China.

Hepatocellular carcinoma (HCC) has high morbidity and mortality rates. It is therefore imperative to study the underlying mechanism of HCC to identify potential prognostic biomarkers and therapeutic targets. Recently, GINS2 has been identified to be a cancer-promoting gene in different cancer types. Read More

View Article and Full-Text PDF

Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates.

Am J Cancer Res 2022 15;12(4):1671-1685. Epub 2022 Apr 15.

Graduate Institute of Biomedical Sciences, China Medical University Taichung, Taiwan.

Triple-negative breast cancer (TNBC) is well-known as the most aggressive subtype of breast cancer. Because TNBC does not express Her2, estrogen receptor, and progesterone receptors, there had been no effective U.S. Read More

View Article and Full-Text PDF

The interaction of and DNA repair gene mutations and their impact on tumor mutation burden and immune response in human malignancies.

Am J Cancer Res 2022 15;12(4):1866-1883. Epub 2022 Apr 15.

Centre for Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London London EC1M 6BQ, UK.

suppresses tumorigenesis through multiple cellular functions/mechanisms, including genomic stability surveillance. Recently, it has also be reported for its role in cancer immune response modulation. Deficiency in DNA repair pathways lead to the accumulation of genomic alterations and tumor mutation burden and in consequence resulting in the activation of immune response. Read More

View Article and Full-Text PDF

Low HECTD1 mRNA expression is associated with poor prognosis and may be correlated with increased mitochondrial respiratory function in breast cancer.

Am J Cancer Res 2022 15;12(4):1593-1605. Epub 2022 Apr 15.

Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences Nagoya, Aichi, Japan.

HECT domain E3 ubiquitin ligase 1 (HECTD1) has been reported to be a negative regulator of epithelial-mesenchymal transition and to decrease breast cancer invasion and metastasis. However, the clinical significance and detailed role of HECTD1 in breast cancer remain elusive. We investigated the role of HECTD1 in two large breast cancer cohorts at our institution and The Cancer Genome Atlas using mRNA expression and bioinformatics analysis. Read More

View Article and Full-Text PDF

Characterizing the mutational landscape of MM and its precursor MGUS.

Am J Cancer Res 2022 15;12(4):1919-1933. Epub 2022 Apr 15.

Laboratory Oncology Unit, Dr. B.R.A. IRCH, AIIMS New Delhi 110029, India.

Mutational Signatures and Tumor mutational burden (TMB) have emerged as prognostic biomarkers in cancer genomics. However, the association of TMB with overall survival (OS) is still unknown in newly diagnosed multiple myeloma (NDMM) patients. Further, the change in the mutational spectrum involving both synonymous and non-synonymous mutations as MGUS progresses to MM is unexplored. Read More

View Article and Full-Text PDF

Pyroptosis impacts the prognosis and treatment response in gastric cancer via immune system modulation.

Am J Cancer Res 2022 15;12(4):1511-1534. Epub 2022 Apr 15.

State Key Laboratory of Cancer Biology and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University Xi'an, Shaanxi, China.

Pyroptosis plays a vital role in the development of cancers; however, its role in regulating immune cell infiltration in tumor microenvironment (TME) and pyroptosis-related molecular subtypes remain unclear. Herein, we comprehensively analyzed the molecular subtypes mediated by the pyroptosis-related genes (PRGs) in gastric cancer (GC). Three pyroptosis patterns were determined with distinct TME cell-infiltrating characteristics and prognosis. Read More

View Article and Full-Text PDF

Everolimus combined with 5-aza-2-deoxycytidine generated potent anti-tumor effects on ovarian clear cell cancer stem-like/spheroid cells by inhibiting the COL6A3-AKT-mTOR pathway.

Am J Cancer Res 2022 15;12(4):1686-1706. Epub 2022 Apr 15.

Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University Taipei, Taiwan.

Ovarian clear cell cancer stem-like/spheroid cells (OCCCSCs) were associated with recurrence, metastasis, and chemoresistance in ovarian clear cell carcinoma (OCCC). We evaluated the anti-tumor effects of 5-aza-2-deoxycytidine (5-aza-dC) combined with everolimus (RAD001) on human OCCC. We investigated parental OCCCSCs and paclitaxel-resistant cell lines derived from OCCCSCs and . Read More

View Article and Full-Text PDF

A manzamine-derived compound as a potential therapeutic agent for glioma by inducing apoptosis and cell cycle arrest.

Am J Cancer Res 2022 15;12(4):1740-1751. Epub 2022 Apr 15.

School of Medicine, Chang Gung University Taoyuan, Taiwan.

Glioma is a severe disease with a poor prognosis despite aggressive surgical resection and traditional chemotherapies. Therefore, new anti-neoplastic drugs are urgently needed. Bioactive compounds from natural products are potential sources of antiproliferative molecules, among which manzamine compounds extracted from the Formosan marine sponge Haliclona sp. Read More

View Article and Full-Text PDF

Association of mutation with better clinical outcomes in pan-cancer for immune checkpoint inhibitors.

Am J Cancer Res 2022 15;12(4):1766-1783. Epub 2022 Apr 15.

Department of Oncology, The First Affiliated Hospital of Nanjing Medical University Nanjing, Jiangsu, China.

Kinase insert domain receptor (KDR) activation is associated with the immunosuppressive microenvironment. However, the efficacy of immunotherapy in patients with mutations is still unclear. To investigate the relationship between gene mutations and the prognosis of pan-cancer, and whether immune checkpoint inhibitors (ICIs) may improve the prognosis of patients with mutations, we analyzed public cohorts of pan-cancer immunotherapeutic patients including genomic and clinical data. Read More

View Article and Full-Text PDF

Construction of AP003469.4-miRNAs-mRNAs ceRNA network to reveal potential biomarkers for hepatocellular carcinoma.

Am J Cancer Res 2022 15;12(4):1484-1501. Epub 2022 Apr 15.

Department of General Medicine, Affiliated Hospital of Zunyi Medical University 149 Dalian Road, Huichuan District, Zunyi 563003, Guizhou, China.

Studies have reported that the competing endogenous RNA (ceRNA) networks are related to disease progression and prognosis in patients with hepatocellular carcinoma (HCC). The roles and mechanisms of long-chain non-coding RNA AP003469.4 in HCC have remained unclear. Read More

View Article and Full-Text PDF